XML 51 R40.htm IDEA: XBRL DOCUMENT v3.24.3
Collaborative Arrangements - AstraZeneca PLC (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Dec. 31, 2023
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Cost of sales $ 4,080 $ 4,264 $ 11,365 $ 12,214  
Selling, general and administrative 2,731 2,519 7,952 7,700  
Research and development 5,862 3,307 13,354 20,904  
Other current assets 40,361   40,361   $ 32,168
Accrued and other current liabilities 16,539   16,539   15,766
AstraZeneca | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Revenue from collaborative arrangement 376 325 1,061 958  
Cost of sales 82 82 245 230  
Selling, general and administrative 39 44 121 143  
Research and development 19 23 57 65  
Other current assets 375   375   341
Accrued and other current liabilities 615   615   256
Other noncurrent liabilities 0   0   $ 600
AstraZeneca | Alliance revenue - Lynparza | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Revenue from collaborative arrangement 337 299 947 884  
AstraZeneca | Alliance revenue - Koselugo | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Revenue from collaborative arrangement $ 39 $ 26 $ 114 $ 74